NCT00523237View on ClinicalTrials.gov

RAL-eve Study: Raltegravir Substitution Study

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

December 31, 2010

Conditions
HIV Infections
Interventions
DRUG

Raltegravir

400 mg Twice daily for 24 weeks

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00523237 - RAL-eve Study: Raltegravir Substitution Study | Biotech Hunter | Biotech Hunter